Who Optimizes SG&A Costs Better? ImmunityBio, Inc. or Viridian Therapeutics, Inc.

Biotech Giants: A Decade of SG&A Cost Management

__timestampImmunityBio, Inc.Viridian Therapeutics, Inc.
Wednesday, January 1, 201443260007751000
Thursday, January 1, 201522620600010251000
Friday, January 1, 2016943910009575000
Sunday, January 1, 20175382100010912000
Monday, January 1, 20183546300011049000
Tuesday, January 1, 20194645600011646000
Wednesday, January 1, 20207131800013265000
Friday, January 1, 202113525600025805000
Saturday, January 1, 202210270800035182000
Sunday, January 1, 202312962000094999000
Loading chart...

Unveiling the hidden dimensions of data

Optimizing SG&A Costs: A Tale of Two Biotech Companies

In the competitive world of biotechnology, managing Selling, General, and Administrative (SG&A) expenses is crucial for financial health. ImmunityBio, Inc. and Viridian Therapeutics, Inc. have taken different paths in this regard over the past decade. From 2014 to 2023, ImmunityBio's SG&A expenses fluctuated significantly, peaking in 2015 with a staggering 2.26 billion, while Viridian maintained a more consistent approach, with expenses rising steadily to 95 million by 2023.

ImmunityBio's expenses saw a dramatic increase of over 5000% from 2014 to 2015, highlighting a period of aggressive expansion or restructuring. In contrast, Viridian's expenses grew by approximately 1100% over the same period, indicating a more controlled growth strategy. This comparison underscores the importance of strategic financial management in the biotech sector, where every dollar counts towards innovation and development.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025